Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597484 | 0.83 | TYR (0.47) | GABRA1GABRB2TYRPRKCIESR1 | |
| SCHEMBL23919938 | 0.83 | AMY1A (0.47) | TYRESR1ESR2TRPA1AMY1A | |
| SCHEMBL4888228 | 0.83 | TYR (0.47) | GABRA1GABRB2TYRPRKCIESR1 | |
| SCHEMBL5195485 | 0.82 | TYR (0.52) | TYRPRKCI | |
| SCHEMBL31620170 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2TYRPRKCITRPA1 | |
| SCHEMBL70108 | 0.81 | TYR (0.60) | GABRA1GABRB2TYRPRKCIESR1 | |
| SCHEMBL7623340 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2TYRPRKCITRPA1 | |
| SCHEMBL27810457 | 0.81 | TYR (0.41) | TYRTRPA1AMY1A | |
| SCHEMBL2475390 | 0.80 | GABRA1 (0.56) | GABRA1GABRB2PRKCIESR1ESR2 | |
| SCHEMBL29719025 | 0.80 | GABRA1 (0.56) | GABRA1GABRB2PRKCIESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102040495-A | Method for synthesizing vanillin by using glyoxylic acid and guaiacol together | TIANJIN PROFESSIONAL COLLEGE | 2011-05-04 | — | — | CN | claimed |
| CN-103275808-A | Mixed-type oily beef essence and preparation method thereof | TIANJIN CHUNYU FOOD INGREDIENTS CO LTD | 2013-09-04 | — | — | CN | disclosed |
| CN-103261181-A | Derivatives of epichlorohydrin of natural origin | SOLVAY | 2013-08-21 | — | — | CN | disclosed |
| CN-102040495-A | Method for synthesizing vanillin by using glyoxylic acid and guaiacol together | TIANJIN PROFESSIONAL COLLEGE | 2011-05-04 | — | — | CN | disclosed |
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | GABRA1 3633/4885GABRB2 3569/4885TYR 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.